TCRX
TScan Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.39
+5.55%Year over year
Reported trailing growth
- Revenue
- +2.2%
- EBITDA
- +14.2%
- EBIT
- +16.4%
- EPS
- +16.5%
- Free cash flow
- +9.8%
- Operating cash flow
- +7.8%
Forward estimates
Based on analyst estimates
- Revenue
- -22.2%
- EBITDA
- -6.6%
- EPS
- -5.8%
Three-year CAGR
- Revenue
- -8.6%
- EBITDA
- -3.7%
- EBIT
- -0.7%
- Net income
- -1.8%
- EPS
- +12.3%
- Free cash flow
- -21.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026